NeuroBo Pharmaceuticals Inc (NRBO)
2.22
-0.17
(-7.11%)
USD |
NASDAQ |
Nov 15, 16:00
2.20
-0.02
(-0.90%)
After-Hours: 20:00
NeuroBo Pharmaceuticals Research and Development Expense (TTM): 21.36M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 21.36M |
| June 30, 2024 | 19.14M |
| March 31, 2024 | 13.42M |
| December 31, 2023 | 9.158M |
| September 30, 2023 | 5.598M |
| June 30, 2023 | 3.877M |
| March 31, 2023 | 2.495M |
| December 31, 2022 | 2.778M |
| September 30, 2022 | 4.47M |
| June 30, 2022 | 5.293M |
| March 31, 2022 | 6.323M |
| December 31, 2021 | 6.546M |
| September 30, 2021 | 22.33M |
| June 30, 2021 | 22.20M |
| March 31, 2021 | 20.86M |
| December 31, 2020 | 21.87M |
| September 30, 2020 | 17.67M |
| June 30, 2020 | 17.55M |
| Date | Value |
|---|---|
| March 31, 2020 | 17.83M |
| December 31, 2019 | 17.48M |
| September 30, 2019 | 5.30M |
| June 30, 2019 | 7.692M |
| March 31, 2019 | 10.70M |
| December 31, 2018 | 13.88M |
| September 30, 2018 | 17.56M |
| June 30, 2018 | 20.51M |
| March 31, 2018 | 22.38M |
| December 31, 2017 | 22.69M |
| September 30, 2017 | 22.44M |
| June 30, 2017 | 17.89M |
| March 31, 2017 | 12.84M |
| December 31, 2016 | 8.74M |
| September 30, 2016 | 5.365M |
| June 30, 2016 | 4.798M |
| March 31, 2016 | 4.961M |
| December 31, 2015 | 4.899M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.495M
Minimum
Mar 2023
22.33M
Maximum
Sep 2021
12.91M
Average
15.45M
Median
Research and Development Expense (TTM) Benchmarks
| Dermata Therapeutics Inc | 5.648M |
| Cognition Therapeutics Inc | 45.40M |
| ZyVersa Therapeutics Inc | 2.153M |
| Cytokinetics Inc | -- |
| Ocugen Inc | 33.34M |